Roivant Sciences Ltd. Q1 FY27 Results

Summary

Roivant Sciences reported its financial results for the first quarter ended June 30, 2026, highlighting significant progress in its clinical development pipeline and a strong cash position. Commercial preparations for brepocitinib in dermatomyositis are on track for a September 2026 launch, with key topline data expected from multiple studies in the second half of the calendar year. The company also noted a substantial $950 million payment received from Moderna as part of a patent settlement. While R&D and G&A expenses increased, the company maintained a robust cash balance of $3.9 billion, supporting its runway into profitability.

Key Highlights

1. 1

   Commercial preparations for brepocitinib in dermatomyositis are progressing well and on track for launch by the end of September 2026.

2. 2

   Topline data from Phase 3 studies in non-infectious uveitis and cutaneous lupus erythematosus are expected in the second half of calendar year 2026.

3. 3

   Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with an additional $1.3 billion contingent on a favorable resolution of Moderna’s § 1498 appeal.

4. 4

   Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $3.9 billion as of June 30, 2026, supporting cash runway into profitability.

5. 5

   Research and development expenses increased by $49.1 million to $202.0 million for the three months ended June 30, 2026, compared to $152.9 million for the same period in 2025.

6. 6

   General and administrative expenses increased by $31.5 million to $165.5 million for the three months ended June 30, 2026, compared to $134.0 million for the same period in 2025.

7. 7

   Net loss was $290.6 million for the three months ended June 30, 2026, compared to $273.9 million for the three months ended June 30, 2025.